Urothelial | Maryland Oncology Hematology Urothelial – Maryland Oncology Hematology

Trial ID ESR 22-21698 (EIMPRIS)

clinicaltrials.gov ID
Phase II/III

Trial ID 20172

clinicaltrials.gov ID
USOR ID: 20172 Phase I/II
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

Quality Care Close to Home

View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology